Thomas Garner - 09 Dec 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Stock Option (Right to Buy)	Award	$0	+235,849		$0.000000	235,849	09 Dec 2024	Common Stock	235,849	$18.76	Direct	F1
transaction	ACAD	Restricted Stock Units	Award	$0	+45,372		$0.000000	45,372	09 Dec 2024	Common Stock	45,372		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	25% of the shares subject to the Stock Option granted under the 2024 Equity Incentive Plan (the "Plan") will vest and become exercisable on December 9, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2	Each restricted stock unit granted under the Plan represents a contingent right to receive one share of the Issuer's common stock.
F3	50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028.